Termsslug: ai-drug-discovery

AI Drug Discovery

AI 制药

Paradigm using machine learning to predict molecular structure, binding affinity and druggability to accelerate preclinical R&D.

Curated Intelligence

6 items · Page 1/1
The DecoderT2·Industry
78 pts
Isomorphic Labs Raises $5 Billion in Second Mega-Round Within Six Months

Alphabet's AI drug discovery unit Isomorphic Labs closed a $5 billion round co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new backer alongside Alphabet and all existing investors. It is the company's second billion-dollar raise in six months, following $2.1 billion in May 2026, and the capital will advance its in-house IsoDDE platform and push its drug pipeline toward clinical trials.

TechCrunch AIT2·Industry
78 pts
Isomorphic Labs Raises $5B to Push AI-Designed Drugs Into Clinical Trials

Isomorphic Labs, the AI drug-discovery company spun out of Google DeepMind in 2021, has closed a $5 billion Series C co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining and all existing backers participating. Building on AlphaFold, its simulation-model engine has produced positive preclinical results in oncology and immunology and underpins deals with Eli Lilly, Novartis and Johnson & Johnson; the new capital is aimed at moving candidates into clinical trials.

IT之家 · IT业界T2·Industry
78 pts
Isomorphic Labs Raises $5 Billion in Series C Funding

Isomorphic Labs, Alphabet's AI-driven drug discovery unit led by Nobel laureate Demis Hassabis, has closed a $5 billion Series C round co-led by Greenoaks and Sequoia Capital, with a16z joining as a new investor and Alphabet continuing to commit heavily. The proceeds will fund foundational simulation models, expand internal and partnered drug candidate programs, and build global AI-driven bioengineering infrastructure.

IT之家 · 智能时代T2·Industry
52 pts
Anthropic CEO's Ten-Year Cancer Cure Claim Draws Medical Pushback

Anthropic CEO Dario Amodei predicted AI will make cancer, Alzheimer's and heart disease history within a decade, echoing optimistic timelines from Musk and Hassabis. Drug-industry executives and physicians pushed back, arguing AI can only speed early molecule screening and cannot bypass the 10-12 year clinical trial and regulatory pipeline; as of 2026 no AI-designed drug has reached full clinical use.

The Verge AIT2·Industry
68 pts
Google and Meta Invest $300M in Zuckerberg's Biohub for AI Biology

Google DeepMind, Meta, and Isomorphic Labs jointly invested $300 million into Mark Zuckerberg's nonprofit Biohub to build large-scale AI datasets for digital biological research. This funding is part of a broader $1.8 billion initiative, signaling deep collaboration among tech giants on AI-driven biomedical infrastructure.